Aap Implantate Ag · XETR:AAQ1
Aap Implantate — H1 2019 Earnings Presentation
10 slides from Aap Implantate's earnings presentation, Aug 14, 2019
Slide 1: aap Implantate AG Q2/H1 2019 Report Conference Call
aap Implantate AG Q2/H1 2019 Report Conference Call Rubino Di Girolamo, CEO Marek Hahn, CFO Berlin, August 14, 2019
Slide 2: Safe Harbor Statement
Safe Harbor Statement Our publication may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual
Slide 3: Key results and progress Q2/H1 2019 (1/2)
Key results and progress Q2/H1 2019 (1/2) ➢ Sales and Earnings ▪ Q2 sales of EUR 2.5 million (Q2/2018: EUR 2.7 million) and EBITDA of EUR -2.1 million (Q2/2018: -1.5 million) at the lower end of the guidance ▪ H1 sales up by +10% to EUR 6.0 million, EBITDA at EUR -3.1 million (H1/2018: -3.1 million)
Slide 4: Key results and progress Q2/H1 2019 (2/2)
Key results and progress Q2/H1 2019 (2/2) ➢ LOQTEQ® ▪ FDA approval for polyaxial LOQTEQ® VA foot system – Launch in US and further markets planned for beginning of 2020 ▪ Continuous focus on adaptation of processes and documents to new regulatory requirements of MDR and development of sterile packag
Slide 5: Financial Figures Q2/2019
Financial Figures Q2/2019 (in KEUR) Sales Q2/2019 Q2/2018 Change Trauma 2,490 2,678 -7% Germany 728 735 -1% North America 620 621 0% North America distributors 614 584 +5% North America global partners 6 37 -84% International (without North America) 1,142 1,322 -14% Europe (without Germany) 451 493
Slide 6: Financial Figures H1/2019
Financial Figures H1/2019 (in KEUR) Sales H1/2019 H1/2018 Change Trauma 5,941 5,473 +9% Germany 1,480 1,391 +6% North America 1,266 1,149 +10% North America distributors 1,244 1,095 +14% North America global partners 22 54 -59% International (without North America) 3,195 2,933 +9% Europe (without Ge
Slide 7: Highlights Q2/H1 2019 (Balance Sheet)
Highlights Q2/H1 2019 (Balance Sheet) ➢ Total assets 30/06/2019: EUR 43.4 million (31/12/2018: EUR 42.2 million) → +3% ▪ Non-current assets: Increased, but countervailing effects − Capitalized development costs: EUR +0.5 million; mainly silver project − First-time application IFRS 16 – Leasing: Pres
Slide 8: Highlights Q2/H1 2019 (Cash Flow)
Highlights Q2/H1 2019 (Cash Flow) ➢ Operating Cash Flow H1/2019: EUR -1.8 million (H1/2018: EUR -2.3 million) ▪ Unchanged operating result (EBITDA) ▪ Positive contribution from working capital of EUR 1.7 million → reduction of inventory (EUR +0.6 million), strongly decreased receivables (EUR +1.1 mi
Slide 9: Outlook FY/2019
Outlook FY/2019 FY/2019 – Sales: EUR 11.0 million – EUR 13.0 million (FY/2018: EUR 10.8 million) – EBITDA: EUR -6.0 million – EUR -5.0 million (FY/2018: EUR -6.4 million) 9
Slide 10: Many thanks for your attention!
Many thanks for your attention! Lorenzweg 5 • 12099 Berlin • Germany Fabian Franke Manager Investor Relations Tel.: +49 30 750 19 – 134 Fax: +49 30 750 19 – 290 E-Mail: ir@aap.de IR-app: 10